drugset / Trial / NCT00097747

Safety and Pharmacokinetics of Single Intravenous Doses of Peginesatide in Healthy Volunteers

NCT00097747

Phase 1 Completed 28 enrolled Affymax
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and minimum pharmacologically active dose of peginesatide in Healthy Volunteers.

Timeline

Start
2004-08
Primary completion
2005-01
Completion
2005-01

Drugs

EvaluationDrugModalityDoseRoute
Subject peginesatide Peptide 0.025 mg/kg Intravenous
Subject peginesatide Peptide 0.05 mg/kg Intravenous
Subject peginesatide Peptide 0.1 mg/kg Intravenous